

## Index

- 21st Century Cures Act of 2016, US, 1
- 3 M Corporation  
 HELP system, 438
- Abe, Shinzu, 219
- Abele, John, 334
- Accountable Care Organizations (ACOs), 431
- Adalimumab  
 rheumatoid arthritis, 104, 107, 108, 110, 117
- adenosine deaminase deficiency (ADA), 105
- Adrenoleukodystrophy (ALD)  
 gene therapy, 106
- Aetna, 459
- Africa, 263
- Agency for Science, Technology and Research  
 (A\*STAR)(Singapore), 222
- aging, population  
 and healthcare, 74
- alliances  
 benefits of, 167  
 biotechnology and pharmaceutical companies, history,  
 171  
 challenges facing, 177  
 collaborative, 167  
 strategic, increasing value, 184
- Alzheimer's disease  
 drug development, 111  
 medical devices, 355
- Amazon, 77, 78, 316, 325, 394, 460, 475  
 healthcare IT, 454  
 medical devices, 393
- American Home Products, 138, 316
- American Medical Association, 28, 358, 424
- American Recovery and Reinvestment Act of 2009  
 (ARRA) (US), 163, 431
- American Society of Gene & Cell Therapy, 123
- AML (acute myelogenous leukemia), 134
- Amsterdam, Netherlands, 207
- amyotrophic lateral sclerosis (ALS) (Lou Gehrig's disease),  
 259  
 drug development, 111
- Anderson, William French, 105
- anemia, 104  
 biosimilars, 256  
 EPO, epigen, 137  
 treatments for, 105
- antisense and RNA interference (RNAi), 129
- Apple, 56, 394, 430, 460  
 healthcare apps, 444
- Asia, 60, 148, 200, 216, 217, 219, 233, 236, 240, 252, 263,  
 289, 290, 294  
 healthcare IT market, 465
- Atlas Venture, 100, 154, 164
- Australia, 233, 235, 236  
 Biomedical Translation Fund, 234  
 biotechnology sector, overview, 233  
 drug approval policies, 235  
 Entrepreneur Visa Program, 234  
 gene therapy, 105  
 IPOs, 219  
 Medical Research Future Fund, 234  
 National Innovation and Science Agenda, 234  
 SME Strategic Intervention, 236
- autoimmune disease, 104  
 Humira, 108
- AVXS-101, 2
- Bakken, Earl, 334
- Bayh-Dole Act of 1980, 94
- Berlin, Germany, 212
- Berners-Lee, Tim, 316
- Bestbuy, 325
- beta-interferons, 104
- Bio-economy Action Plan  
 India, 237
- biologics, follow-on (FOBs)  
 insurance coverage, 259
- Biomedical Translation Fund (Australia), 234
- biopharmaceutical companies  
 Amgen, 48, 95, 105, 136, 137, 163, 188, 199, 241, 258,  
 316  
 China, 230

- Amgen, biosimilars, 256
- Amgen, Neupogen, 257
- Amgen, Neupogen, Neulasta, 256
- Amgen, settlement with AbbVie, 258
- Biogen, 48, 89, 95, 104, 108, 144, 145, 163, 171, 199, 199, 241, 311, 316
  - location in Cambridge, MA, 316
- Celgene, 52, 124, 184, 185, 193, 226, 233, 233, 262
  - deal-making, 184
- Celgene, orphan diseases, 262
- Celgene, regenerative medicine, 254
- Centocor, 95, 108, 110, 138
- Centocor, Centoxin, 138
- Cetus, 95, 162
- Chiron, 95
- facilities/biopharmaceutical manufacturing, 54
- Genetics Institute, 95, 105, 108, 137, 137
- Gilead, 48
- Repligen, 95
- Vertex, 41, 48, 130, 186, 241
  - outsourcing, 55
- biopharmaceutical products
  - forms, 55
- biopharmaceutical sector
  - Japan, R&D, 220
  - value of deals, 2016, 95
- Biopolis (Singapore), 223
- biosimilars, 32, 55, 57, 178, 178, 238, 238, 246, 247, 247
  - approval, 247
  - Australia, 235
  - European Medicines Agency, 247
  - India, 237, 238
  - market in Asia, 217
  - regulatory process, 255
  - South Korea, 240
  - US regulation, 256
- Biosimilars Price Competition and Innovation Act of 2009, 57
- Biotechnology
  - antisense and RNA interference (RNAi), 131
  - beta-interferons, 104
  - cell therapy, 123
  - combinatorial chemistry, 130
  - CRISP/Cas9, 125, 127
  - gene editing, 125
  - gene therapy, 128
  - genetic engineering, 90
  - history of, 91
  - proteomics, 129
  - rational drug design (RDD), 130
  - research institutes and foundations, 113
  - single cell sequencing, 128
  - biotechnology companies
    - Abgenix, 117
    - Ablexis, 148
    - Actelion, 202, 213
    - Adimab, 117
    - Affymetrix, 122
    - Agiros, 134, 185
    - Alkermes, 202, 251
      - value-based pricing, 251
    - Alnylam, 132, 133, 163, 250, 280
      - Onpattro, development, 250
    - Althea Technologies, 221
    - Ambit Biosciences, 221
    - Ambys Medicines, 187
    - Asterias Biotherapeutics, 253
    - AstraZeneca, 205, 280, 316
      - China, 230
    - Avidity Biosciences, 221
    - BASF, 108, 110
    - BeiGene, 226, 229, 231, 233, 290, 291
    - BFI Shenzhen, 122
    - Bharat Biotech, 239
    - Biomatics Capital, 113
    - Bluebird Bio, 124
    - Blueprint Medicines, 187
    - BTG, 202
    - business models, platform technology, 139
    - Cambridge Antibody Technology, 117
    - Collectis, 213
    - Celltech, 108
    - Chi-Med, 229
    - Clementia, 215
    - Constellation Pharmaceuticals, 135
    - CRISPR Therapeutics, 127, 186
    - CSL, 235
    - Denali, 155
    - Dyax, 117
    - Editas Medicines, 127, 186
    - Elan Corp., 104
    - EMD Serono, 104
    - Epizyme, 135
    - ES Cell International, 252
    - Galapagos, 213
    - Genentech, 89, 91, 92, 95, 139, 161, 171, 172, 189, 190, 190, 192, 199, 231, 245, 311
      - Roche, 190
    - Genovo, 106
    - GenSight, 213
    - Genzyme, 111, 163, 262, 311, 316
      - location in Cambridge, MA, 316
    - Geron Corporation, 253
    - Gilead, 48, 123, 124, 147, 188, 193, 339
    - Hoechst AG, 314
    - Horama, 213

- biotechnology companies (cont.)
  - Horizon Pharma, 202
  - Human Genome Sciences, 173
  - Illumina, 122
  - Imclone, 175, 177
  - Immunex, 110, 163, 199
  - ImmunoMet, 134
  - Intellia Therapeutics, 127
  - Ipsen, 195, 202, 214
  - Jazz, 202, 382
  - Juno Therapeutics, 124, 155, 186, 193
  - Kite, 123, 124
  - Kyn Therapeutics, 134
  - Life Technologies, 122
  - Lysogene, 213
  - MediTech, 226
  - MerLion, 223
  - Monsanto, 314
  - Nanjing Legend Biotech, 124, 226
  - Neurocrine Biosciences, 174
  - Novozymes, 202
  - PvP Biologics, 221
  - Qiagen, 202
  - Resolvix, 162
  - Rheos Medicines, 134
  - S\*BIO, 223
  - Sangamo, 125, 125
  - Shire Pharmaceuticals, 117, 193, 202
    - merger with Takeda, 221
    - orphan diseases, 262
  - Sima, 132, 133
  - Spark Therapeutics, 2, 107
  - Spinifex, 235
  - Strand Life Sciences, 238
  - Tessa Therapeutics, 223
  - The Medicines Company, 145, 146
  - ThermoFisher Scientific, 122
  - Zafgen, 148
  - Zymeworks, 215
- biotechnology drugs
  - number of, 101
- Biotechnology Industry Research Assistance Council (BIRAC)
  - India, 237
- Biotechnology Promotion Law of 1983 (South Korea), 239
- biotechnology sector
  - alliances, 167
  - and academic institutions, 111
  - and pharmaceutical sector, 99
  - anemia, treatment, 105
  - Asia, 99, 216
  - Australia, 99, 233
  - biologic checkpoint therapy, 101
  - business models, FIPCO, 136, 137, 139, 148
  - business models, NRDOs, 136, 145
  - business models, overview, 135
  - business models, pure technology platform model, 136
  - business models, RIPCOs, 136, 143, 144, 148
  - Cares Acceleration Network (CAN), 247
  - Canada, 99
    - financing/overview, 215
  - capital markets, 149
  - cell therapy, 101, 123
  - China, 99
    - overview, 224
  - clinical trials, number of, 102, 111
  - cost to bring a drug to market, 149
  - definition of, 96
  - drug pipeline, 112
  - EU, Brexit effect on, 207
  - economic clusters, 310, 312
  - effect on drug pricing, 111
  - employment, 111
  - Europe, 99
    - Europe, Bioeconomy Strategy and Action Plan, 204
    - Europe, employment, 202
    - Europe, Horizon 2020, 204
    - Europe, investments, 202
    - Europe, patents, 202
    - Europe, sales and growth, 202
  - financial performance, 97
  - financing, 149
    - financing, drug royalty monetization, 162
    - financing, Euronext, 213
    - financing, government grants, 163, 163
    - Financing, PIPES, 160
    - financing, private placement, 158
    - financing, R&D limited partnerships, 161
    - financing, SBIR grants, 163
    - financing, SWORD, 161
    - financing, the public market, 156
    - financing, venture capital (VC), 152
  - France, financing, 213
    - France, Inserm, 214
    - France, overview, 212
  - gene therapy, 101, 105, 128
  - genome editing, 125
  - genomics, 118
  - Germany, 209
    - Germany, BioRegions, BioParks, 210
    - Germany, HTGF, venture capital, 212
    - Germany, life sciences, 212
  - global, 99
    - government initiatives and growth, 201
    - growth/structure, 200
  - immuno-oncology therapy, 101
  - impact on healthcare, 102
  - impact on pharmaceutical sector, 112

- importance of time in success rate, 90
- increasing approval of new drugs, 182
- India, 99, 236
- innovation, overview, 112
- intellectual property, 92
- introduction to, 89
- investment in, 99
- Japan, 218
- Korea, government support, 240
- leadership, CEO, 197, 197
- licensing deals, 100
- mergers and acquisitions (M&A), value of deals, 100
- new discoveries, data, 90
- new venture creation, 303
- number of biologics and vaccines approved, 102
- number of drugs, 102
- organizational development, 306
- overview, 96
- patents, history/importance of, 92
- private philanthropy, 112
- regulation and policy, 241
- relationship with pharmaceutical sector, 166
- research and development, 99
- revenues, US, 101
- Singapore, overview, 222
- single gene sequencing, 128
- size, 99
- South Korea, general, 239
- startups, 25
- Therapeutic Discovery Tax Credit, 247
- therapeutics, 25
- UK data, 205
- US, 200
- venture capital, growth in, 154
- venture capitalists, 100
- virtual model, 147
- Bio-Vision 2016 (South Korea), 240
- Blair, Henry, 311
- blindness
  - drugs, 2
  - gene therapy, 106
  - Luxturna, 107
- Booth, Bruce
  - Atlas Venture, 164
- Boston Consulting Group, 314
- Boston Scientific, 355
  - cost of sales staff, 357
- Boston, Massachusetts, 23, 101, 154, 164, 194, 195, 317
  - early cluster formation, 316
  - economic clusters, 317
  - research hubs, 195
- Boyer, Herbert, 91, 311
  - Genentech, 192
- Brailer, David, 431
- Brazil
  - medical device sector, 354
- Brenner, Sydney, 222
- Brexit referendum, 207, 208, 287
  - effect on biotechnology sector, 207
  - UK, potential drawbacks, 208
- British Columbia, Canada, 216
- Broad Institute, 122, 125, 195
- business models, 307
  - platform companies, 308
  - product companies, 309
- California, 23, 92, 111
  - stem cell research, 252
  - biotech cluster, 314
- Cambridge, Massachusetts, 25, 108, 122, 127, 148, 277, 314, 316, 317, 318
  - Biogen, 144
  - biopharma venture capital funding, 317
  - Cambridge Innovation Center, 316
  - Kendall Square, 314, 318, 319, 320
  - research hubs, 195
- Cambridge Antibody Technologies (CAT), 108
- Canada, 72, 200, 215, 215, 216, 461, 463
  - biotechnology sector, 214
  - economic clusters, 318
  - healthcare IT, 463
  - R&D, 216
  - venture capital, 215
- cancer, 102, 105, 122, 123, 124, 127, 128, 129, 134, 223, 233, 283, 417
  - cancer metabolism, 134
  - drugs, prices, 178
  - Erbitux, 175
  - G-CSF, 137
  - Germany, therapies, 212
  - lymphoma, 106
  - melanoma, 103
  - multiple myeloma, 103
  - neurostim, 343
  - novel drugs, 250
  - Opdivo approval in UK, 207
  - population health management, 448
  - stomach, 220
  - Takeda Pharmaceuticals, 143
  - therapies, 187
  - TNF, cytokine, 108
- cardiovascular disease, 102
- Cares Acceleration Network (CAN), 247
  - research in China, 230

- Car-T, 2, 123, 124, 125, 183, 186, 193, 291  
   Kymriah, 2, 123  
   Yescarta, 123
- CAR-T therapy  
   advanced multiple myeloma, 124  
   Rosenberg group, 124  
   T-cell receptor (TCR), 124
- cell therapy, 123
- Center for Biologics Evaluation and Research (CBER) (US), 245
- Center for Drug Evaluation and Research (CDER) (US), 245
- Center for Medicare and Medicaid Services (CMS) (US)  
   reimbursement, 424
- Central Drugs Standard Control Organization (CDSCO) (India), 238
- Chakrabarty, Ananda, 92
- Chan, Priscilla, 164
- Charpentier, Emmanuelle, Dr.  
   CRISPR/Cas9, 125
- chemotherapy, 103
- China, 1, 23, 148, 218, 222, 224, 226, 230, 231, 234, 238, 291, 318  
   biotech investment, 229  
   biotechnology growth plans, 216  
   biotechnology sector, 224  
   government and biotechnology, 201  
   Health China 2030, 226  
   ICH, 264  
   innovation, 230  
   life sciences research, 225  
   medical device sector, 354  
   medical devices, 335, 338  
   National Drug Reimbursement List (NDRL), 231  
   patents, 210  
   regulatory system for IP, 217
- China, IPOS, 219
- chronic obstructive pulmonary disease (COPD), 64, 79, 178  
   Nucala, 177
- clinical trials  
   database, 52
- Cohen, Stanley, 92, 311
- Coleman, Alan, 252
- Colorado  
   value-based pricing, 251
- combinatorial chemistry, 130
- congestive heart failure (CHF), 77, 329, 337, 345  
   medical devices, 329
- contract administration fees (CAFs), 22
- Copenhagen, Denmark, 194
- Crick, Francis, 91
- CRISPR/Cas 9, 140
- Crohn's disease, 104, 110
- CVS, 280, 459
- cystic fibrosis, 102, 103, 186, 259
- de Silva, Ashanti  
   gene therapy trial, 105
- Deloitte, 284  
   pharmaceutical R&D productivity, 180
- Dementia  
   population health management, 448
- Denmark  
   economic clusters, 318
- Department of Agriculture (US), 242
- Department of Biotechnology (DBT) (India), 237
- Department of Defense, US, 163
- Department of Homeland Security (US), 163
- depression  
   medical devices, 331
- diabetes  
   glucose monitors, continuous, 325  
   population health management, 448  
   wearable patch pumps, 325
- diabetic macular edema  
   Macugen, 174
- diagnosis-related groups (DRGs), 430
- disease models, 34
- DNA  
   discovery of, 91  
   rDNA, 91
- Doudna, Dr. Jennifer  
   CRISPR/Cas9, 125
- drug approval  
   international harmonization, 262
- drug approval testing  
   phases of, 35
- drug formulary, 58
- drug prices  
   rise in, 20
- drug pricing, 65  
   value-based pricing, 250
- drugs  
   Ablynx, 183  
   Abraxane, 233  
   Amjevita, 258  
   Avonex, 199  
   Biologic License Applications (BLAs), 180  
   Bioerativ, 183  
   Cialis, 373  
   Eliquis, 77  
   Enbrel, 199  
     competition with, 178  
   Erbitux, 175  
   generics, 178, 179, 255  
   Glybera  
     LPLD, 212

- Harvoni, 339  
 Herceptin, 104, 192  
 Humira, 89, 102, 107, 111, 163, 178, 209, 258  
   competition with, 178  
 Ibrance  
   pricing, 178  
 Indiplon, insomnia, 174  
 Lantus, 62  
 Levemir, 62  
 Levitra, 373  
 Lipitor, 364  
 Macugen, 174  
 Neulasta, 256  
 Neupogen, 137, 256, 257  
 New Drug Applications (NDAs), 180  
 Nucala, COPD, 177  
 Onpatro, 250  
 Opdivo, 207  
   pricing, 178  
 Remicade, 163, 178, 258  
   competition with, 178  
 Revlimid, 233  
 Rituxin, 199  
 Sovaldi, 339  
 tPA, 190, 199, 245  
 Tylenol, 373  
 Viagra, 373  
 Vidasa, 233  
 volanesorsen, FCS, 177  
 Zaxxio (filgrastim-sndz), 257  
 drugs, prescription  
   spending, US, 249
- Eclipsys, 438  
 economic clusters  
   the Triple Helix, 313, 314  
 Egypt  
   medical devices, 338  
 Electronic health records (EHRs), 431  
   adoption of, 432  
 Environmental Protection Agency (U.S.), 242  
 epigenetics, 134, 135  
 Epilepsy  
   medical devices, 325, 331  
   neurostim, 343  
 Erythropoietin, 105  
 Europe, 29, 61, 71, 99, 111, 112, 145, 167, 200, 202, 202,  
   205, 207, 209, 210, 213, 214, 216, 218, 241, 265, 270,  
   286, 299  
   drug regulation, 262  
   EMA, drug approval, 265  
   German biotechnology sector, 209  
   governments and biotechnology, 202  
   healthcare IT market, 465  
   ICH, 263  
   medical device regulation, 390  
   medical devices, 335  
   patents, 210  
 European Commission, 265  
   drug regulation laws, 267  
   EMA, 266  
   Horizon 2020, 204  
   ICH, 263  
   marketing authorization, 211  
 European Economic Area (EEA), 208  
 European Federation of Pharmaceutical Industries'  
   Associations (EFPIA)  
   ICH, 263  
 European Medicines Agency (EMA), 207, 247  
   biosimilar approval, 256
- Fabry's disease, 259, 262  
 Feldman, Mark  
   University of Oxford, 108  
 Film, 80  
 financial companies/firms  
   Celtic, Royalty Pharma, 162  
 financing companies  
   500 Startups, 218  
   BioScience Manager Fund, 235  
   Brandon Capital Partners, 235  
   Hanmi Ventures, 240  
   Medical Research Commercialization Fund, 235, 235  
   One Ventures Capital, 235  
   Sofinnova, 213  
 Flagship Pioneering, 100  
 follow-on biologics (FOBs). *See* biosimilars  
 Food and Drug Administration (FDA) (US), 53, 57, 58,  
   104, 106, 117, 123, 124, 128, 133, 135, 138, 152, 171,  
   175, 177, 177, 180, 182, 219, 223, 240, 242, 243, 244,  
   245, 247, 249, 250, 253, 255, 256, 257, 260, 260, 271,  
   299, 321, 331, 388, 389, 390, 391, 408  
   biologics, 255  
   biosimilar approval, 256  
   CBER, CDER, 245  
   Chinese drugs, 230  
   clinical testing, 423  
   drug approval, compared to Japan, 220, 271  
   drugs approved, 134  
   expedited approval pathways, 177  
   generic approval process, 179, 255  
   ICH, 263  
   Medical Device Act, 326  
   medical device regulation, 387, 388, 389, 391  
   medical devices, Unique Device Identification  
     Database, 408  
   NeoTract, 404  
   new drugs approved, 197

- Food and Drug Administration (FDA) (US) (cont.)  
 novel biologic drugs, 247  
 orphan diseases, 259  
 orphan drug research, 260  
 PDUFA, 242  
 Recombinant DNA Advisory Committee, 128  
 reduced drug approval time, 243  
 regulation of biotechnology, 242  
 regulatory approval, 423  
 Reveal LINQ™ ICM System, 415  
 Right to Try Bill, 249  
 risk evaluation and mitigation, 244  
 Sentinel Initiative, 244  
 stem cell research, 253  
 timeliness and safety concerns, 243
- Fortune 500 companies, 22
- Fragile X syndrome, 259
- France, 23, 72, 205, 207, 212, 213, 214  
 biotechnology sector, 212  
 financing, 214  
 gene therapy, 105, 106  
 Genomic Medicine 2025, 214  
 patents, 210
- G7 countries  
 drug distribution, 75
- Gates Foundation, 113, 164
- Gates, Bill, 164
- Gaucher's disease, 103, 259  
 Cerezyme, 111
- Gelsinger, Jesse  
 clinical study, 105
- gene therapy, 128  
 AVXS-101, 2  
 blindness, 106  
 CAR-T, 106  
 Leber's congenital amaurosis, 106  
 Parkinson's disease, 106  
 SCID ("bubble boy" disease), 106
- General Electric (GE), 40, 92
- Genetic testing companies  
 12 and Me, 122  
 CRIGenetics, 122  
 Family Tree DNA, 122  
 Living DNA, 122
- genome editing, 125
- Genome Institute, Singapore, 252
- genome-wide association (GWA), 121
- genomics, 118  
 alliances between biotechnology and pharmaceutical  
 companies, 172  
 cost, 121  
 Human Genome Project, 118
- George Washington University, 438
- German Research Foundation, 210
- Germany, 72, 205, 207, 209, 211, 212, 212, 213, 214  
 Arzneimittelmarkt-Neuordnungsgesetz (AMNOG),  
 212  
 BioParks, 210  
 BioRegions, 210  
 biotechnology sector, 209  
 biotechnology sector investment, 202  
 biotechnology sector, statistics, 210  
 government and biotechnology, 201  
 life sciences, 212  
 medical devices, 333
- Germany, High-Tech Gründerfonds (HTGF), 212
- Gilbert, Walter, 311  
 Biogen, 144
- GKV, German health insurance, 210  
 reimbursement, 211
- Golub Todd,  
 Foundation Medicine, 122
- Google, 316, 460  
 medical devices, Verily, 394
- group purchasing organizations (GPOs), 22
- Harvard, 300, 311, 314, 318, 319
- HCV, 79
- healthcare apps, 445
- Health Information Technology for Economic and  
 Clinical Health (HITECH) Act (US), 431
- Health Insurance Portability and Accountability Act  
 (HIPAA), 431
- healthcare  
 and population aging, 74  
 information technology (IT), 429
- healthcare reform  
 impact on medical device sector, 391  
 PPACA, 392  
 US, 246  
 pharma and biotech expansion, 246
- healthcare sectors  
 similarities and differences, 4
- healthcare spending  
 biggest categories, 18
- healthcare spending, US  
 data, 70
- healthcare, US  
 market size, 418
- hepatitis, 64, 102, 103, 144
- hepatitis B, 102, 104, 144
- hepatitis C, 104, 339
- hereditary edema  
 ecallantide, 117
- Heywood, Ben, 446
- Heywood, James, 446
- Heywood, Stephen, 446

- HIMSS Analytics, 432  
 HIV, 12, 102, 104  
 Horizon 2020, 204, 208, 286  
 Human Genome Project, 118  
   India, 238  
 Humira (Adalimumab), 107  
 Huntington's disease, 259  
 hypertension, 12, 417  
 Hyundai, 240
- Iceland, 208  
 Independent Payment Advisory Board (IPAB), 248  
 India, 148, 236, 238, 239, 241, 294, 461, 463, 476  
   Bio-economy Action Plan, 237  
   biosimilars, 238  
   Biotechnology Industry Research Assistance Council, 237  
   biotechnology sector, 236  
   Central Drugs Standard Control Organization (CDSCO), 238  
   Department of Biotechnology (DBT), 237  
   government and biotechnology, 201  
   healthcare IT, 463  
   healthcare sector, 237  
   ICH, 264  
   IPOs, 219  
   medical device sector, 354  
   medical devices, 338  
   regulatory process, 238  
   regulatory system for IP, 217  
   Review Committee on Genetic Manipulation, 238  
 Indianapolis, Indiana, 194  
 inflammatory bowel disease, 134  
 infliximab  
   rheumatoid arthritis, 108  
 influenza, 102  
 information technology (IT), healthcare  
   apps, 445  
   business models, 467  
   Canada, 463  
   challenges facing, 455  
   consumers, 442  
   CPOE, 438  
   EHR, ancillary systems, 437  
   electronic health records (EHR), usability issues, 457  
   future growth, 434  
   future of, 468  
   health information exchange (HIE), 447  
   India, 463  
   international adoption, 461  
   Internet of Things (IoT), 450  
   market growth, 465  
   mHealth, 444  
   multistakeholder, 446  
   overview, 429  
   payers, 440  
   population health management, 448  
   practice and revenue cycle management, 439  
   providers, 435  
   role of computers in history of, 430  
   Saas, 453  
   Singapore, 464  
   Taiwan, 464  
   telehealth, 449  
   United Kingdom, 461  
   value-based care, 458  
   virtual communities, 445
- Innovation  
   “effective innovation agenda”, 2  
   antisense and Antisense and RNA interference (RNAi), 131  
   benefits versus affordability, 2  
   biotechnology sector, 91  
   cell therapy, bone marrow transplantation, blood transfusion, 123  
   cell therapy, limitations, side effects, 124, 125  
   China, 230  
   combinatorial chemistry, 130  
   commonalities across sectors, 7  
   cost of first drug approval, 135  
   cost to bring a drug to market, 149  
   Crispr/Cas9, 125  
   cross-selling, 413  
   estimation of impact over time, 10  
   financing, 398  
   gene therapy, 128  
   genome editing, 125  
   genomics, 118  
   in the healthcare value chain, 2  
   innovation gap, 179  
   in-house versus acquired or in-licensed, 79  
   medical device sector, 358  
   monoclonal antibodies (MAbs), 114  
   next generation DNA sequencing, 120  
   personalized medicine, 120  
   pharmaceutical companies adjusting operating models, 196  
   pharmaceutical vs biotechnology sector, 182  
   proteomics, 129  
   public-private partnerships, 112  
   rational drug design (RDD), 130  
   role of geographic clusters, 317  
   single cell sequencing, 128  
   Thiel Foundation Breakout Labs, 113  
 Institute for Human Gene Therapy  
   University of Pennsylvania School of Medicine, 106  
 Institute for Protein Innovation, 113  
 insulin, 79

- Integrated circuit (IC) industry, 56  
 Intermountain Health Care, 438  
 International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 262  
 Internet of Things (IoT), 450  
 Investment companies  
   bpifrance, 213  
   iBionext, 213  
   i-LAB, 213  
 IPOs, 9, 155, 164, 387  
   Australia, 235  
   European biotechnology sector, 202  
   India, 238  
   Japan, life sciences, 219  
   life science investors, 149  
   medical device sector, 383, 386, 426  
   South Korea, 240  
 Italy, 72, 207  
   medical devices, 334  
 Japan, 72, 218, 218, 221, 221, 236, 241, 265, 269, 271, 301  
   Agency for Medical Research and Development (AMED), 220  
   biotechnology sector, overview, 218  
   biotechnology, Cool Japan Fud (CJF), 218  
   Central Social Insurance Medical Council (Chuikyo), 219  
   compared to Australia, 235  
   drug approval, 269  
   drug price reductions, 178  
   drug regulation, 262  
   ICH, 263  
   medical devices, 333  
   Ministry of Health, Labor, and Welfare (MHLW), 219  
   National Cancer Center, 220  
   orphan diseases, 260  
   patents, 210  
   Pharmaceutical and Food Safety Bureau, 270  
   PMDA, 271  
   Prescription Drug and User Fee Act (PDUFA), 219  
   stem cell research, 252, 253  
   Strategy of Sakigate, innovation, 219  
 Japanese Pharmaceutical Manufacturers' Association (JPMA)  
   IPH, 263  
 Johnson & Johnson, 134, 139, 178, 194, 285, 291, 316, 328, 342  
   JLABS, 194  
   medical device trauma products, 328  
   biosimilars, 256  
   Orthoclone OKT3, transplant rejection, 114  
 Johnson, Lyndon  
   Medicare, 429  
 Kamen, Bob, 89, 108  
 Kobe, Japan, 221  
 Köhler, Georges  
   MAbs, 114  
 Korea, 237, 239, 294, 294  
   biotech financing, 240  
   biotechnology growth plans, 216  
   government and biotechnology, 201  
   IPOs, 219  
   patents, 210  
   stem cell research, 252  
 Korean Biotechnology Industry Organization, 239  
 Kymriah, 2  
 Kyoto University, 220  
 Lander, Eric  
   Broad Institute, 195  
   Foundation Medicine, 122  
 Lawrence Ellison Foundation on Aging, 114  
 Leber's congenital amaurosis  
   gene therapy, 106  
 Leibniz Association, 210  
 leucopenia, 103  
 Levin, Mark  
   Millennium, 89  
   Millennium, Third Rock Ventures, 143  
 Liechtenstein, 208  
 Life sciences industry, 24  
 Life Sciences Sector Deal, U.K., 208  
 Liu, Edison, 252  
 London, U.K., 207, 334  
 Lou Gehrig's Foundation, 114  
 lupus, 134  
 Luxturna, 2, 107, 277  
 MAbs, TNF, 108  
 Macau, 233  
 Macular degeneration  
   Macugen, 174  
 Massachusetts, 314, 317  
   biotechnology growth strategy, statistics, 111  
   Department of Economic Development, 316  
   value-based pricing, 250  
 Massachusetts Biotechnology Council, 195  
 Massachusetts Institute of Technology (MIT), 446  
 Materials sciences  
   medical devices, 377  
 Max Planck Institute, 125  
 Max Planck Society, 210  
 McKesson, 440  
 Medical device companies  
   Abbott, 324, 343, 348, 367, 382, 384  
   Abiomed, 341, 346, 369, 371  
   Alere, 384

- American Medical Systems, 380  
 AtriTech, Inc., 413  
 Auris Surgical Robotics, 341  
 Bard, 413  
 Baxter, 316, 331  
 Becton Dickinson, 324, 331, 356, 384, 413  
 Biomet, 331, 368, 369, 382, 413  
 Biotronik, 334, 375  
 Boston Scientific, 331, 343, 356, 367, 369, 375, 380, 381, 384, 413  
 C.R. Bard, 356  
 CareFusion, 413  
 CoreValve, Inc., 413  
 Covidien, 356, 382, 384, 385, 413  
 Cyberonics, 334  
 Danaher, 331  
 Dentsply Sirona, 334  
 Dexcom, 342, 394  
 Edwards Lifesciences, 340, 346, 356, 369, 390, 413  
 Entellus, 385  
 Fresenius, 333  
 Google, 342  
 Guidant, 380, 384  
 Howmedica, 380  
 Intuitive Surgical, 331, 339, 341, 342, 345, 356, 369, 371  
 Johnson & Johnson, 324, 331, 341, 342, 348, 356, 368, 380, 394  
   profits, 359  
   international sales, 354  
   venture financing, 386  
 Lazarus Effect, 386  
 Livanova, 334, 343  
 LMA, 405  
 MAKO Surgical, 341, 385, 414  
 Mazor, 342  
 Medina, 386  
 Medrobotics, 341  
 Medtronic, 324, 331, 333, 334, 335, 342, 343, 348, 353, 367, 375, 379, 380, 382, 383, 384, 385, 413, 415, 416, 417  
   bundling, 417  
   cardiovascular devices, 415  
   Micra™ Transcatheter Pacing System (TPS), 416  
   profits, 359  
   Reveal LINQ™ ICM System, 415  
 Medtronic, Deep Miniaturization program, 415  
 Medtronic, device pricing, 353  
 Medtronic, international sales, 354  
 Medtronic, M&A, 384, 385  
 Medtronic, venture financing, 386  
 Medtronic/Covidien, 356  
 Merit Medical Systems, 386  
 NeoTract, Inc., 404  
 Neuropace, 343  
 Nevro, 343  
 Novocure, 343  
 Orthotaxy, 342  
 Percutaneous Valve Technologies, Inc., 413  
 Philips, 316  
 PhysioControl, 385  
 production and operating expenses, 369  
 relationship between growth and size, 348  
 Restore Surgical, 385  
 Sage, 385  
 selling expenses, 369  
 Shiley, 380  
 Small Bone Innovations, 385  
 Smith & Nephew, 333  
 Sorin, 334  
 St. Jude Medical, 382, 384  
 Straumann Holdings, 334  
 Stryker, 324, 328, 331, 341, 369, 414  
   acquisition of MAKO Surgical, 384, 385, 414  
 Synthes, 328  
 Teleflex, Inc., 403  
 Terumo, 333  
 TransEnterix, 341, 342  
 Vascular Solutions, 404, 405  
 Vidacare, 405  
 Visualase, 385  
 Zimmer, 328, 331, 369, 380, 384, 413  
 Zimmer/Biomet, 368, 382  
 Medical device sector, 25  
   acquisitions and product value, 403  
   AdvaMed, 335  
   Brazil, 354  
   cardiovascular, 327  
   cardiovascular, structural heart devices, 329  
   China, 354  
   compared to other sectors, 324, 359  
   consolidation, 381  
   consumers, customers, and payers, 359  
   corporate structural changes, 356  
   Department of Justice investigation, 323  
   drug/device convergence, 378  
   geographic use, 336  
   government regulation, 407  
   growth drivers, 350  
   growth over time, 345  
   healthcare reform, 391  
   history, 325  
   India, 354  
   innovation, 358  
   innovation and growth, 398  
   innovation ecosystem, 410  
   intellectual property protection, 419  
   international, 332  
   key drivers of acquisitions, 405

- Medical device sector (cont.)  
 large commercial state companies, 412  
 M&A, 382, 383  
 management teams, 421  
 market size, 327  
 marketing and selling strategies, 366  
 materials science, 376  
 Medical Device Innovation Consortium (MDIC), 391  
 NEST, 391  
 orthopedics, 327  
 overview, 321  
 patients, providers, and payers, 407  
 physician education, 368  
 pricing, 399  
 product development, 421  
 profits, compared to pharmaceutical sector, 371  
 recent slowdown, 339  
 reimbursement, 423  
 Research and development (R&D), 347, 356  
 revenues, 322  
   worldwide, 324  
 role of investors, 409  
 Russia, 354  
 segment reshuffling, 355  
 size of, 418  
 small companies, 411  
 statistics, 349  
 technologies, 373  
 venture capital, 417, 419
- Medical devices  
 “Infuse” spine cage, 379  
 Apple Watch, 394  
 cardiac pumps, 341  
 cardiovascular support devices, 330  
 continuous glucose monitoring devices (CGM), 339, 343  
 coronary bypass graft surgery (CABG), 345  
 da Vinci Surgical System, 341  
 deep brain stimulation (DBS), 343  
 defibrillators, 324, 325, 334, 337, 339, 344, 345, 366, 367,  
   369, 371, 374, 388  
 diabetes, CGM, insulin pumps, 342, 347  
 diagnostic equipment, 324  
 drug-eluting stents (DES), 329  
 ear nose and throat (ENT), 346  
 epilepsy, 325  
 extremities, 328  
*Guardian Connect*, 343  
 heart valve replacement, 325  
 hip and knee replacements, 324  
 hip implants, 368  
 hospital supplies, 324  
 implantable defibrillators, 322, 327, 335, 337, 363, 375,  
   393  
 insulin pumps, 364  
 interventional cardiology, 352  
 Libre CGM, 343  
 neuro and robotic surgeries, 331  
 neurological diseases, 343  
 Neurostim, 343, 346  
 pacemakers, 324, 334, 335, 337, 353, 354, 365, 366, 367,  
   369, 370, 371, 374, 375  
 patch pumps, wearable, 325  
 percutaneous structural heart interventions, 340  
 respiratory, 346  
 robotic surgery, 341  
 sacral nerve stimulation (SNM), 343  
 SAPIEN, 390  
 spending, 18  
 spinal, 328  
 spinal cord stimulation (SCS), 343  
 stents, 325, 339  
 transcatheter aortic valve replacements (TAVR), 339, 346  
 transcatheter heart valve, 329, 330, 335, 364  
 UroLift System, 404  
 vascular surgery, 351  
 Watchman, 355, 413  
 wire mesh stents, 322
- Medical Research Future Fund (Australia), 234  
 Medicare (U.S.)  
   healthcare IT, 429  
 Medicare Access and CHIP Reauthorization Act of 2015  
   (MACRA), 431  
 Medicines and Healthcare Products Regulatory Agency  
   (MHRA)  
   U.K., 207
- Medtech sector  
 startups, 26
- Melbourne, Australia, 234
- Mergers and acquisitions (M&A)  
 as strategy, 6  
 biotechnology sector, 100  
 life sciences, number and value over time, 188  
 medical device companies, 383  
 medical device sector, 382, 403, 427  
 pharmaceutical-biotechnology company relationships,  
   188
- Mice, transgenic, 117
- Michigan  
 value-based pricing, 251
- Middle East, 241, 263  
 medical devices, 335
- Milstein, Cesar  
 MAbs, 114
- Ministry of Health, Labor and Welfare (MHLW)  
 ICH, 263
- MIT, 299, 311, 314, 316, 318
- Molecular diagnostic companies  
 Foundation Medicine, 122, 123

- Moll, Frederic*, 341  
 monoclonal antibodies (MAb), 91, 92, 102, 104, 108, 110, 114, 117, 140  
     European Medicines Agency, 247  
     U.S. CDER, 245  
 Montreal, Quebec, Canada, 216  
 Moore's Law, 32  
 multiple sclerosis, 103, 104, 145, 308
- National Cancer Institute, 124, 252  
 National Health Service (NHS), U.K., 206, 461, 462, 476  
     healthcare IT, 461  
 National Innovation and Science Agenda (Australia), 234  
 National Institute for Health and Medical Research (Inserm) (France), 214  
 National Public Radio (NPR), 195  
 neutropenia  
     treatment, 256  
 New venture creation  
     financing, 310  
 New York, 23, 194, 396, 473  
     stem cell research, 252  
     economic clusters, 318  
 NICE, U.K., 72, 87, 178, 206  
     drug approval process, 206  
 Nicholas, Peter, 334  
 National Institutes of Health (NIH) (US), 1, 6, 52, 94, 99, 105, 112, 118, 128, 152, 163, 200, 220, 253, 254, 276, 282, 317  
     Health Consensus Group, 443  
     economic clusters, 317  
     stem cell research, 252, 253  
 Norway, 208  
 Notified Bodies and Ethics Commissions  
     EU, 408  
 Novartis, 2  
 nth compound problem, 51
- Obama, Barack, 246, 253, 254, 323  
     healthcare reform, 391  
     stem cell research, 252  
 Open Payments Act (Sunshine Act), 16  
 Orange Book, 255  
 Ornithine transcarbamylase (OTC) deficiency, 105  
 orphan diseases  
     and healthcare reform, 246  
     Orphan Drug Law, 259  
     small biotech companies, 260  
 Osaka, Japan, 221  
 Outsourcing, 55  
     healthcare IT, 453, 454  
 Oxford, UK, 194  
 Oyler, John  
     BeiGene, 231  
     Parker Institute for Cancer Immunotherapy, 164  
     Parker, Sean, 164  
 Parkinson's disease  
     drug development, 111  
     gene therapy, 106  
     medical devices, 326, 331  
     neurostim, 343  
 Patent Office Board of Appeals (U.S.), 92  
 Patents  
     earnings lost due to expirations, 178  
 Patient Protection and Affordable Care Act (PPACA) (U.S.), 246, 431  
 Patient-Centered Outcomes Research Institute (PCORI), 248  
 Payers  
     contrast between US and Western European systems, 61  
     influence on product selection, 61  
     personal health records (PHRs), 443  
     personalized medicine, 121, 123, 214  
     Germany, 212  
 Peter Bent Brigham Hospital, 438  
 Pharmaceutical companies  
     Abbott Laboratories, 110, 316, 384  
     AbbVie, 102, 178, 258, 316, 325  
     adjusting operating models to foster innovation, 196  
     Agios Pharmaceuticals, 134  
     Alexion, 195  
     Astellas, 221  
     Astellas, regenerative medicine, 254  
     Aventis, 23  
     Azur Pharma PLC, 382  
     Bayer, 173, 221, 373  
     CoLaborator, 194  
     Boehringer Ingelheim, 220  
     Bristol-Myers Squibb, 41, 147, 175, 178, 207, 380  
     Dr. Reddy's Laboratories, 238  
     Eli Lilly, 171, 177, 220, 226, 373  
     Eyeteq Pharmaceuticals, 174  
     GSK, 134, 177, 325  
     Hanmi Pharmaceuticals, 240  
     Ionis Pharmaceuticals, 133, 177  
     Ipsen Pharmaceuticals, 195  
     Istesso Pharma, 134  
     Johnson & Johnson, 57, 105, 226, 373  
     Kite Pharmaceuticals, 124, 193  
     Knoll Pharmaceuticals, 108, 110  
     Lilly, 325  
     Lupin Ltd., 238  
     Merck, 52, 97, 132, 133, 144, 175, 189, 226, 291, 325  
     Millennium, 141, 142, 143, 173  
     Novartis, 2, 23, 123, 124, 133, 180, 196, 316, 325  
     Novo Nordisk, 62, 194

- Pharmaceutical companies (cont.)
- Otsuka, 221
    - Abilify MyCite, 445
  - Pfizer, 52, 97, 134, 174, 178, 179, 189, 316, 364, 373, 380
    - Centers for Therapeutic Innovation, 194
    - China, 230
    - Ventures, 196
      - regenerative medicine, 254
  - Roche, 41, 122, 123, 133, 139, 172, 187, 189, 190, 190, 192, 199
    - Genentech, 190
  - Sanofi, 23, 62, 183, 183, 196, 214, 262
  - Sanofi Sunrise, 196
  - Sanofi Ventures, 196
  - Schering Plough, 144, 171
  - SmithKline French, 173
  - Takeda Pharmaceuticals, 141, 143, 183, 187, 193, 221, 221, 262
    - merger with Shire, 221
    - platform technology, 141
  - Valeant, 382
- Pharmaceutical consumption
- data, 31
- Pharmaceutical companies
- Eli Lilly, 380
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- ICH, 263
- Pharmaceutical sector, 31
- alliances, 167
  - biotechification, 193
  - declining origination of new drugs, 182
  - drugs acquired from biotechnology companies, 112
  - relationship with biotechnology sector, 166
  - research and development (R&D), 31
- Pharmaceuticals
- distribution of, 75
  - Millennium Pharmaceuticals, 173
- pharmacies
- retail versus online, 77
- Pharmaceutical consumption
- data, US, 70
- Pharmacy benefit manager (PBM), 20, 22, 62, 64
- Philadelphia, Pennsylvania, 23, 106, 194
- physicians
- role in pharmaceutical sales, 58
- Population health management, 448
- Porter, Michael, 24, 312
- Prescription drugs
- access to, 70
- PricewaterhouseCoopers, 390
- medical technologies innovation scorecard, 24
- Producer sectors, 4
- producers, healthcare products
- importance of, 15
  - Project BioShield, 163
  - Prospective Payment System (PPS), 11, 430
  - Proteus Digital Health
    - Abilify MyCite, 445
  - psoriasis, 103, 110
- QALY, 71, 72, 250
- value-based pricing, 251
- Rational drug design (RDD), 130
- rDNA, 91, 95, 96, 100, 104, 114, 137, 142, 173
- Reed, John
- Sanofi, 183
- renal disease, 102, 103, 137
- Research and development (R&D)
- and organizational behaviors, 48
  - definition, 6
  - failure rate, 37
  - financing, 161, 162
  - funding for, 6
  - growing investment versus productivity, 179
  - in-house versus acquired or in-licensed, 41
  - in-licensed drugs, 311
  - input costs, 37
  - investment statistics, 179
  - investments in biopharmaceutical sector, 4
  - medical device industry, 347
  - nth compound problem, 51
  - orphan diseases, 260
  - patents, 40
  - pharmaceutical sector, 31
  - seed investing, 304
  - spending increase over time, 34
- Research institutes
- Broad, 195
  - Koch, 195
  - Whitehead, 195
- Review Committee on Genetic Manipulation (RCGM) (India), 238
- rheumatoid arthritis, 102, 103, 108, 110, 134
- adalimumab, 110
  - etanercept, 110
  - Humira, 108
  - infliximab, 110
  - treatment costs, 111
- Richter, Melinda
- Johnson & Johnson, 194
- Right to Try Bill (U.S.), 248
- Rosenberg, Dr. Steven
- adoptive cell transfer (ACT), 124
- Russia, 337
- medical device sector, 354

- Samsung, 56, 240  
 healthcare apps, 444
- San Diego, California, 23, 194, 221  
 Japanese pharmaceutical companies, 221
- San Francisco, California, 91, 101, 148, 194, 282, 476  
 economic clusters, 317
- Saroukas, Costa  
 Takeda, 183
- SCID (“bubble boy” disease)  
 gene therapy, 106
- Science and Technology Diplomatic Circle, 318
- seed investing, 304
- Shanghai, China, 194, 290
- Sharp, Phillip, 311, 316  
 Biogen, 144
- Shepherd Center, Atlanta, 253
- sickle cell disease, 186
- Singapore, 217, 222, 223, 290, 461, 464, 477  
 Agency for Science, Technology and Research (A\*STAR), 222  
 Biopolis, 223  
 biotechnology growth plans, 216  
 Genome Institute, 252  
 government and biotechnology, 201  
 healthcare IT, 464  
 life sciences hub, 224  
 R&D growth, 222  
 SingHealth Investigational Medicine Unit, 223  
 stem cell research, 252
- Singapore Clinical Research Institute, 223
- SingHealth Investigational Medicine Unit (Singapore), 223
- single gene sequencing, 128
- SME Strategic Intervention  
 Australia, 236
- Smith, Benson  
 Teleflex, 405
- South America, 241, 263
- South Korea  
 Biotechnology Promotion Law of 1983, 239  
 biotechnology sector, 239  
 Bio-Vision 2016, 240  
 government support for biotech, 240  
 innovation, 240
- South Korea Food and Drug Administration (KFDA), 240
- Spain, 207  
 medical devices, 337
- spinal muscular atrophy, 2, 103, 106, 133
- Spinraza (nusinersen)  
 spinal muscular atrophy, 133
- Springer, Timothy  
 Institute for Protein Innovation, 113
- Stanford University, 92
- Starr, Kevin  
 Millennium and Third Rock Ventures, 89, 143
- stem cell research, 194, 251  
 Asia, 252  
 California, New York, funding, 252  
 NIH support, 253  
 US policy, 254
- Stott, Kevin  
 Novartis, R&D productivity, 180
- strategy, 45–47
- Swanson, Robert A., 92  
 Genentech, 192
- Switzerland, 108, 127, 205, 205, 209, 213  
 biotechnology sector investment, 202  
 medical devices, 333
- Taiwan, 216, 233, 461, 464, 477  
 healthcare IT, 464
- Tax Cuts and Jobs Act, US, 188, 248, 260
- TCR cell therapies, 186
- technological imperative, 6, 10  
 benefits of new technology, 12  
 government efforts to control costs, 11
- technology clusters, 23
- technology companies  
 Adobe, 324  
 Alphabet, medical devices, 393  
 Apple, 324  
 Apple, medical devices, 393  
 Hewlett-Packard, 324, 325  
 IBM, 324, 325, 343  
 Intel, 56, 324, 325
- technology sectors  
 economic impact of, 23
- Telehealth, 449
- Tepper, Bob  
 Millennium and Third Rock Ventures, 89, 143
- The Chan-Zuckerberg BioHub, 164
- The Cystic Fibrosis Foundation, 114
- The Fraunhofer-Gesellschaft, 210
- The Helmholtz Association, 210
- the Netherlands  
 economic clusters, 318
- The Thousand Talents Plan (China)
- Therapeutic Discovery Tax Credit, US, 247
- Thiel Foundation Breakout Labs, 113
- Third Rock Ventures, 89, 100, 143, 154
- Thirteenth Five-Year Plan (China), 1
- Thomas, Dr. E. Donnell  
 first bone marrow transplantation, 123
- Toronto, Ontario, Canada, 194, 216
- Tufts University, 149, 311
- Twelfth Five-Year Plan (China), 1

- United Kingdom, 72, 178, 205, 205, 206, 207, 208, 212, 213, 214, 216  
 biotechnology VC investment, 202  
 gene therapy, 105  
 healthcare IT, 461  
 patents, 210  
 United States–Korea Free Trade Agreement, 240  
 Uhl, Steve  
 Advamed, 390  
 United States Supreme Court, 92  
 UnitedHealthcare, 459  
 University of California, 125  
 University of California, San Francisco, 92  
 University of Indiana, 438  
 University of Oxford, 108  
 University of Pennsylvania, 106  
 gene therapy, 106  
 University of Pennsylvania School of Medicine, 106
- value chain, 1, 2, 15, 16, 22, 23, 24, 31, 32, 33, 79, 80, 81  
 biotechnology and pharmaceutical company relationship, 167  
 biotechnology business models, 136  
 medical devices, 364  
 venture creation, 307
- value-based care  
 healthcare IT, 458
- value-based pricing (VBP), 251
- Venture capital (VC), 152  
 Alaska Permanent Fund, 155  
 medical technology, 417
- Venture capital firms  
 Third Rock Ventures, 143
- Venture capital funds  
 American Research and Development Corporation, 316
- Venture creation  
 biotechnology sector, 303  
 organizational development, 306
- Vincent, James  
 Biogen, 144
- Vitravene (formivirsen)  
 antisense, 133
- Walmart, 325
- Wang, Xiaodoing  
 BeiGene, 231
- Wanless, Derek, 461
- Watson, James, 91
- Welch, Jack  
 General Electric, 40
- Worcester, Massachusetts  
 biotechnology research and manufacturing, 108
- World Health Organization (WHO), 34, 262  
 ATC classification scheme, 40
- Yamanaka, Shinya, 253
- Zhang, Feng, Dr.  
 CRISP/CAS9, 125
- Zhangjiang Hi-Tech Park, 318
- Zika, 239
- Zillmer, Chris  
 Medtronic, 415
- Zuckerberg, Mark, 164